Aeternus (GHK + MOTS + NAD)
Cellular. Whole. Without surrender.
- Sizes available
- —
- Lab certificate (COA)
- Arrives with shipment
· Research-grade only · Not for human consumption · 21+ ·
GHK-Cu + MOTS-c + NAD 3-compound longevity stack.
Mechanism · Combined longevity blend. Copper-binding + mitochondrial + sirtuin cofactor.
Best for. Not for.
Best for
- Users pursuing multi-mechanism longevity (cosmetic, mitochondrial, and sirtuin)
- Aeternus protocol users
- Users who want multiple mechanisms in a single injection
Not for
- Per components. Active malignancy, pregnancy, or nursing
- Copper allergy
- Complex stack with difficult per-compound dosing
Mechanism, dose, ramp, risk.
- Mechanism
- Three-compound longevity stack. See /protocols/aeternus.Source · PEPVERA editorial
- Target dose
- Per protocol.Source · PEPVERA editorial
- Ramp
- 12-Week cycle.Source · PEPVERA editorial
- Risks
- Per components.Source · PEPVERA editorial
Compared to its siblings.
Aeternus (GHK + MOTS + NAD)
GHK-Cu + MOTS-c + NAD 3-compound longevity stack.
Pros
- · Multi-mechanism coverage beyond NAD's single sirtuin pathway.
- · Broader than the single mitochondrial pathway of MOTS-c.
Cons
- · No commercial OTC presence like Niagen or Basis.
- · Less targeted than a single-compound mitochondrial peptide.
NAD+
Single sirtuin cofactor. Proven brand.
Pros
- · Commercial OTC (Niagen / Basis)
Cons
- · Single mechanism
See NAD+ →
MOTS-c
Single mitochondrial peptide.
Pros
- · Targeted
Cons
- · Pre-clinical
See MOTS-c →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 0 suppliers
No verified suppliers yet for this compound.
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
Per protocol.
Initiation
Week 3–4
Per protocol.
Signal emerges
Week 5–8
Per protocol.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
2 mg = 0.20 mL at 10.00 mg/mL. 10.0 doses per vial.
eternal · X
Aeternus (GHK + MOTS + NAD) · 20mg